Posted by Michael Wonder on 28 Jun 2019
Highlights from the 24-27 June CHMP meeting
28 June 2019 - EMA’s CHMP recommended three medicines for approval at its June 2019 meeting.
The Committee recommended granting a marketing authorisation for Giapreza (angiotensin II), for the treatment of refractory hypotension in adults with septic or other distributive shock.
The CHMP adopted a negative opinion recommending the refusal of a marketing authorisation for Evenity (romosozumab). Evenity was expected to be used to treat osteoporosis.
